Abstract 451: Pde1 Promotes Development of Pulmonary Arterial Hypertension and Could Be a Novel Treatment Target

Backgrounds: Pulmonary arterial hypertension (PAH) is a rare but fatal disease, with an estimated mean survival period in untreated patients of approximately 3 years. Pulmonary vascular remodeling ...